Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, has expanded its collaboration with AmplifyBio, a rapidly growing contract development and manufacturing organization, through the installation of a new AVATAR Foundry system as part of Xcellbio’s beta access program.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
